Anil Nair

Anil Nair, MD is researcher on Alzheimer's Disease and neurology at Boston University.
His areas of interest are new drugs and genetics of Alzheimer's Disease. He is the primary investigator for the DHA and IVIG studies which evaluates new drugs for Alzheimer's disease.
Dr. Nair is also investigator for several other Alzheimer's disease drug treatment trials including ADAPT, Flurizan, immunotherapy and IVIG studies in which new medications are being tested for preventing Alzheimer's disease. He is also an investigator in the HOPE study. He also works with the REVEAL Study (Risk Evaluation and Education for Alzheimer's disease), a multi-center project funded by the National Human Genome Research Institute and the NIA to evaluate genetic risk assessment strategies for individuals at risk for Alzheimer's disease by disclosing their APOE information. He is also an investigator with the ADNI trial, which is an NIH funded, 5 year observational study of mild cognitive impairment and early Alzheimer’s disease, by repeated imaging, biological markers and clinical assessments to measure the progression.

Main Menu

See Also

Main Menu